Global Medical REIT Inc.
Find Ratings ReportsGLOBAL MEDICAL REIT's gross profit margin for the third quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line.
During the same period, stockholders' equity ("net worth") has decreased by 5.73% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 35.51 | 35.41 |
EBITDA ($mil) | 13.81 | 14.53 |
EBIT ($mil) | 9.71 | 10.24 |
Net Income ($mil) | 4.59 | 9.51 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 17.47 | 21.26 |
Total Assets ($mil) | 1302.52 | 1406.75 |
Total Debt ($mil) | 625.22 | 695.87 |
Equity ($mil) | 611.45 | 648.67 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | 51.19 | 52.53 |
EBITDA Margin | 38.89 | 41.03 |
Operating Margin | 27.36 | 28.92 |
Sales Turnover | 0.11 | 0.09 |
Return on Assets | 1.67 | 1.6 |
Return on Equity | 2.62 | 2.58 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 0.0 | 0.0 |
Debt/Capital | 0.51 | 0.52 |
Interest Expense | 7.17 | 6.96 |
Interest Coverage | 1.35 | 1.47 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 65.57 | 65.52 |
Div / share | 0.21 | 0.21 |
EPS | 0.05 | 0.12 |
Book value / share | 9.33 | 9.9 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 362390.0 | 304558.0 |
HOLD. This stock's P/E ratio indicates a significant discount compared to an average of 49.19 for the Real Estate subsector and a premium compared to the S&P 500 average of 27.95. For additional comparison, its price-to-book ratio of 0.93 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 6.43. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. Upon assessment of these and other key valuation criteria, GLOBAL MEDICAL REIT proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GMRE 34.72 | Peers 49.19 | GMRE 8.29 | Peers 18.58 | |||||||||||||||||||||
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. GMRE is trading at a significant discount to its peers. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. GMRE is trading at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
GMRE 289.33 | Peers 40.04 | GMRE NM | Peers 5.86 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. GMRE's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. GMRE's negative PEG ratio makes this valuation measure meaningless. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
GMRE 0.93 | Peers 6.43 | GMRE 0.00 | Peers -7.55 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. GMRE is trading at a significant discount to its peers. |
Neutral. Higher earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. The growth rate for GMRE is not available. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
GMRE 3.94 | Peers 7.79 | GMRE 9.95 | Peers 11.68 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. GMRE is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. GMRE trails its peers on the basis of sales growth. |
|||||||||||||||||||||||